Drugs / DB959
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02560753 | Jul 2015 → May 2016 | Alzheimer disease | T3D Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04251182 | Mar 2021 → Jan 2023 | Alzheimer disease | T3D Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06964230 | Oct 2026 → Apr 2031 expected | Alzheimer disease | T3D Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-07-22 | T3D Therapeutics, Inc. | Results T3D Therapeutics Announces Presentation of Final Phase 2a Results of T3D-959 in Mild to Moderate Alzheimer’s Subjects at the 2018 Alzheimer’s Association International Conference t3dtherapeutics.com ↗ |
| 2016-06-23 | T3D Therapeutics, Inc. | Regulatory T3D Therapeutics Receives FDA Approval for a 6-Month, Open-Label Extension to its Phase 2a Trial of T3D-959 for Treatment of Mild to Moderate Alzheimer’s Disease t3dtherapeutics.com ↗
T3D Therapeutics has received FDA approval for an open-label, 26-week extension study in mild to moderate Alzheimer’s disease patients extending its Phase 2a feasibility study of T3D-959 |
All press releases naming this drug 14 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB959 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545176 ↗ |
| Known as | T3D-959 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06964230 ↗ |
| Action | Activate | “T3D-959's targeting neuro-metabolic dysfunctions via agonism of PPAR delta and PPAR gamma nuclear receptors provides potential disease modification in AD.” PMID 27525190 ↗ Jun 20162“Peroxisome proliferator-activated receptor delta agonist” CHEMBL3545176 ↗ “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL3545176 ↗ |
| Modality | Small molecule | “small molecule dual nuclear receptor agonist” NCT02560753 ↗ |
| Route | Oral | “orally-delivered, once-a-day administered” NCT02560753 ↗ |
| Target | PPARD | “Peroxisome proliferator-activated receptor delta agonist” CHEMBL3545176 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL3545176 ↗ |